Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA. …
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity
November 15, 2025 - - Australian Biotech -
Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose
November 15, 2025 - -
PYC reports sustained vision gains in RP11 clinical trial
November 15, 2025 - - Australian Biotech -
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
Prospection says data access and leadership are critical to unlock AI’s potential in healthcare
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments
November 14, 2025 - - Latest News